Prof. Jyoti Chattopadhyaya from Uppsala University and colleagues from India have synthesised modified siRNAs targetting the TAR region of HIV-1, some of which exhibit a four-fold enhanced half-life in serum over the native unmodified siRNA. The best compound synthesised had an IC50 more than three-fold lower than that of the native and two-fold lower than that of the existing locked nucleic acid (LNA) modified counterpart. The strategy to chemically modify the native siRNAs by substitution with the jcLNA can be considered as a significant development, leading to both enhanced siRNA efficiency and serum stability over that of the native. Read more in MedChemComm.
adaptive immunity Alzheimer's Disease antibiotics apoptosis autism bacteria Breast cancer C. elegans Caenorhabditis elegans cancer chromatin circadian clocks CRISPR cryo-electron microscopy DNA dopamine Drosophila Epigenetics eukaryotes evolution gene expression Genomics HIV HIV AIDS human genome immunity metabolism microRNA miRNA mitochondria mRNA neural circuits neurodegeneration neurons obesity optogenetics Parkinson's Disease pathogenesis proteomics ribosomes RNA stem cells synapses transcription vaccines